Targovax announces presentation of pre-clinical data from Next Generation ONCOS at AACR Virtual Annual Conference
Oslo, Norway, 24 June 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, announces that data from a pre-clinical study with next-generation ONCOS-200 series viruses with novel anti-cancer double-transgenes was presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting. The pre-clinical in vitro and in vivo findings demonstrated that both ONCOS-210 & ONCOS-212 have anti-cancer properties and that the double transgenes act synergistically. The encouraging preclinical